Glioblastoma genetics: in rapid flux.
Glioblastoma is the most common and most lethal primary brain tumor. While small progress has been made in treating this cancer in recent years, glioblastoma remains largely resistant to all existing therapies. It has been hoped that dissection of the genetics of this cancer would lead to more targeted and effective treatments, and new advances may finally be bringing this closer to fruition. Within the last few years, high-throughput efforts such as The Cancer Genome Atlas and a massive sequencing project have yielded novel insights and classifications of this dreaded cancer. The likely impact on care delivery in the clinic may only be a few years away. The rapid and exciting pace of advances in glioblastoma genetics has prompted this up-to-date review.
Purow
Benjamin W
BW
Neuro-Oncology Center, Department of Neurology, University of Virginia, Charlottesville, Virginia 22908, USA. bwp5g@hscmail.mcc.virginia.edu
Schiff
David
D
D000970:Antineoplastic Agents / Q000494:pharmacology; D001932:Brain Neoplasms / Q000235:genetics* / Q000628:therapy*; D044127:Epigenesis, Genetic; D015894:Genome, Human; D005909:Glioblastoma / Q000235:genetics* / Q000628:therapy*; D006801:Humans; D008495:Medical Oncology / Q000379:methods; D035683:MicroRNAs / Q000378:metabolism; D008957:Models, Genetic; D009154:Mutation; D011379:Prognosis; D013577:Syndrome
D000970:Antineoplastic Agents; D035683:MicroRNAs